NCT00223548

MESNA for Prevention of Acute Deterioration of Renal Function Following Contrast Agent Application

MESNA Zur Prophylaxe Der Kontrastmittel-Induzierten Nephropathie

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 106 (planned)
• Sponsor: University of Ulm · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine wether Mesna could prevent contrast-induced nephropathy

Detailed description

Contrast-induced nephropathy remains a common complication of radiographic precedures. Pretreatment with Mesna (Sodium 2-mercaptoethane sulfonate) in combination with sodium chloride is more protective than sodium chloride alone in animal models of acute renal failure. The aim of this study is therefore to determine laboratory and clinical benefit of MESNA, as an adjunct to saline hydration, in patients with known renal impairment receiving contrast media.

Conditions

• Chronic Renal Insufficiency
• Serum Creatinine Concentration
• Contrast Media Exposition

Interventions

Type	Name	Description
DRUG	sodium 2-mercaptoethane sulfonate

Timeline

• Start date: 2002-10-01
• Completion: 2004-12-01
• First posted: 2005-09-22
• Last updated: 2005-09-22

Locations

1 site across 1 country: Germany